Company: SINT
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010496
Chunk: 5

Company: Sintx Technologies, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 8
Chunk 5
---
Common Stock”),
pre-funded warrants to purchase 278,098 shares of Common Stock (the “Pre-Funded Warrants”) with an exercise price of $0.0001
per share, and warrants to purchase 1,449,287 shares of Common Stock (the “Common Warrants,” together with the Pre-Funded
Warrants, the “Warrants”) (the Warrants, together with the Shares and Warrant Shares (as defined below), the “Securities”)
with an exercise price of $3.32 per share. The purchase price per share of Common Stock and the associated Common Warrant was $3.45 and
the purchase price per Pre-Funded Warrant and associated Common Warrant was $3.4499. The Common Warrants are exercisable immediately and
expire five-and one-half years from issuance. The Pre-Funded Warrants are exercisable immediately and terminate when exercised in full.

We are actively seeking opportunities to raise additional
equity and/or debt financing. However, such funding is not guaranteed and may not be available to the Company on favorable or acceptable
terms and may involve significant restrictive covenants. Any additional equity financing, if available to the Company, will most likely
be dilutive to its current stockholders. If the Company is not able to obtain additional debt or equity financing on a timely basis, the
impact on the Company will be material and adverse.

    9

The Board of Directors, together with management,
is performing an ongoing evaluation of the Company’s business strategy and focus.

An option being evaluated is a change in strategic
emphasis to advancements in the medical device sector. Historically engaged in both industrial and biomedical applications, SINTX would
prioritize the development and commercialization of innovative medical devices, leveraging our expertise in advanced ceramics and biomaterials.
Such a renewed focus would align with a commitment to improving patient outcomes through the creation of products designed for surgical,
orthopedic, and other specialized medical applications. We would concentrate our resources on high-growth areas within the healthcare
sector where our proprietary materials and technologies—such as silicon nitride—provide a distinct competitive advantage due
to their unique strength, durability, and biocompatibility.

Through this transformation, SINTX’s aim would
be to deliver meaningful innovations to the medical community. Our current research and development pipeline is centered on medical-grade
devices that incorporate antimicrobial properties, enhanced imaging capabilities, and durability under physiological conditions, which
are critical for orthopedic implants